Attending Physician at Children's Hospital of Philadelphia; Assistant Professor, Perelman School of Medicine at the University of Pennsylvania
Children's Hospital of Philadelphia
Despite the use of intensive multimodal therapy for neuroblastoma, approximately one-half of children still die from this disease. Dr. Bosse's laboratory focuses on the development of new immune-based therapies for this embryonal malignancy of the developing nervous system. Through these studies, Dr. Bosse and his colleagues hope to both improve their understanding of the critical biologic mechanisms driving neuroblastoma tumorigenesis and to translate new transformative immunotherapeutics to the clinic.
Children’s Hospital of Philadelphia
GPC2 as an Immunotherapeutic Target in Medulloblastoma and other Pediatric Brain Tumors
GPC2 is a molecule expressed on the surface of cells in medulloblastoma and neuroblastoma cells. Researchers will analyze specimens provided by the Children’s Brain Tumor Network in an effort to determine whether GPC2 could serve as an immunotherapeutic target for the treatment of such tumors.
Medulloblastoma, HGG, (AT/RT)
Medulloblastomas comprises the vast majority of pediatric embryonal tumors and by definition arise in the posterior fossa, where they constitute approximately 40% of all posterior fossa tumors. Other forms of embryonal tumors each make up 2% or less of all childhood brain tumors.The clinical feature
High-grade Gliomas (HGG) or astrocytomas in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric-specific HGG preclinical models. These models are needed to help test
Atypical Teratoid/Rhabdoid Tumor
Central nervous system (CNS) atypical teratoid/rhabdoid tumor (AT/RT) is a very rare, fast-growing tumor of the brain and spinal cord. It usually occurs in children aged three years and younger, although it can occur in older children and adults. About half of these tumors form in the cerebellum or
Frontiers in Oncology
CAMKV is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
We developed a computational pipeline designed to use RNA sequencing (n = 136) and gene expression profiling (n = 250) data from neuroblastoma tumors to identify cell surface proteins predicted to be highly expressed in MYCN amplified neuroblastomas and with little or no expression in normal human t
Sussman RT, Rokita JL, Huang K, Raman P, Rathi KS, Martinez D, Bosse KR, Lane M, Hart LS, Bhatti T, Pawel B, Maris JM.